Cargando…
Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091100/ https://www.ncbi.nlm.nih.gov/pubmed/36647206 http://dx.doi.org/10.1002/cac2.12406 |
| _version_ | 1785023085041156096 |
|---|---|
| author | Iwasa, Satoru Wang, Zi‐Xian Muro, Kei Morita, Satoshi Park, Young Suk Zhang, Dongsheng Yamada, Yasuhide Sakamoto, Junichi Kim, Tae Won |
| author_facet | Iwasa, Satoru Wang, Zi‐Xian Muro, Kei Morita, Satoshi Park, Young Suk Zhang, Dongsheng Yamada, Yasuhide Sakamoto, Junichi Kim, Tae Won |
| author_sort | Iwasa, Satoru |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10091100 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100911002023-04-13 Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study Iwasa, Satoru Wang, Zi‐Xian Muro, Kei Morita, Satoshi Park, Young Suk Zhang, Dongsheng Yamada, Yasuhide Sakamoto, Junichi Kim, Tae Won Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2023-01-16 /pmc/articles/PMC10091100/ /pubmed/36647206 http://dx.doi.org/10.1002/cac2.12406 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Iwasa, Satoru Wang, Zi‐Xian Muro, Kei Morita, Satoshi Park, Young Suk Zhang, Dongsheng Yamada, Yasuhide Sakamoto, Junichi Kim, Tae Won Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study |
| title | Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study |
| title_full | Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study |
| title_fullStr | Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study |
| title_full_unstemmed | Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study |
| title_short | Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study |
| title_sort | impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or folfiri with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the axept study |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091100/ https://www.ncbi.nlm.nih.gov/pubmed/36647206 http://dx.doi.org/10.1002/cac2.12406 |
| work_keys_str_mv | AT iwasasatoru impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT wangzixian impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT murokei impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT moritasatoshi impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT parkyoungsuk impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT zhangdongsheng impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT yamadayasuhide impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT sakamotojunichi impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy AT kimtaewon impactofpriorchemotherapywithtwodifferentfluoropyrimidinesontheefficacyofcapecitabineplusirinotecanorfolfiriwithorwithoutbevacizumabinmetastaticcolorectalcanceraposthocanalysisoftheaxeptstudy |